-
Epigenetic MCL-1 Targeting in Glioblastoma
2026-09-10
The reference study identifies a super-enhancer near Mcl-1 as a transcriptional vulnerability in glioblastoma and shows that THZ1-mediated MCL-1 suppression sensitizes tumors to BCL-2/BCL-XL inhibition. Its chromatin, mitochondrial apoptosis, and patient-derived xenograft data support a context-dependent synthetic-lethal strategy while highlighting important limits for translation.
-
Dhcr7 Knockout Grass Carp Resists GCRV
2026-09-09
A 2026 Aquaculture Reports study used CRISPR/Cas9 and an in vivo GCRV-II challenge to validate Dhcr7 as a molecular target for disease-resistant grass carp breeding. Dhcr7-disrupted fish showed higher survival, stronger Irf3-associated antiviral responses, lower viral burden, and reduced hepatopancreas injury without detectable effects on measured growth or muscle morphology.
-
Cisplatin (CDDP): DNA Damage Workflows
2026-09-09
Build more interpretable Cisplatin experiments by separating DNA damage, pathway adaptation, and cell death readouts. This workflow connects CDDP-based apoptosis assays and xenograft studies with the Wnt–EGFR DNA-damage framework described in Drosophila, while offering practical preparation, optimization, and troubleshooting guidance.
-
Coumestrol in RA-FLS Ferroptosis Research
2026-09-08
Coumestrol connects estrogen receptor pharmacology with a practical ferroptosis workflow in rheumatoid arthritis fibroblast-like synoviocytes. This guide translates the TRIM3–PMAIP1 finding into assay design, formulation control, mechanistic validation, and troubleshooting decisions.
-
740 Y-P for PI3K/AKT Assay Design
2026-09-08
Use 740 Y-P as a cell-permeable PI 3-kinase activator to connect PI3K signaling with survival, vesicular trafficking, and mitophagy phenotypes. This practical guide translates chondrocyte pyroptosis findings into controlled workflows for cancer research, neuronal cell survival, and pathway-validation experiments.
-
Mitochondrial Calcium Signaling and Ferroptosis
2026-09-07
The reference study identifies a direct mechanistic connection between mitochondrial calcium uptake, acetyl-CoA metabolism, GPX4 acetylation, and suppression of ferroptotic cell death. Its genetic, antioxidant-rescue, biochemical, structural, and tumor-model evidence suggests that MCU-dependent metabolic signaling sustains GPX4 activity and can influence tumor growth.
-
Cabazitaxel (XRP6258) Workflow Guide
2026-09-05
Cabazitaxel (XRP6258, SKU B2157) provides a dossier-based workflow for studying microtubule dynamics disruption and antiproliferative responses, including in P-glycoprotein-expressing or taxane-resistant models. It is suited to validated DMSO- or ethanol-based preparations and should not be introduced into aqueous assays or retained as a long-term solution without separate formulation and stability work.
-
Dual HER2–VEGFR-2 Targeting in Breast Cancer
2026-09-05
The reference study examines Lapatinib and Telatinib as a dual tyrosine kinase inhibition strategy for suppressing migration-associated phenotypes in triple-negative breast cancer cells. Its most informative finding is that reduced proliferation, invadopodia formation, and 2D tube formation can occur in an MDA-MB-231 model lacking HER2, highlighting both the potential and the mechanistic uncertainty of phenotype-first targeted cancer therapy research.
-
MG-262: Reversible Proteasome Inhibition
2026-09-04
MG-262, also called Z-Leu-Leu-Leu-B(OH)2, is a reversible, cell-permeable boronic peptide acid inhibitor of proteasome chymotryptic activity. Its defined mechanism and handling profile support proteasome inhibition assay design, apoptosis research, and studies of ubiquitin-dependent proteostasis.
-
Propidium Iodide in PCOS: From Cell Fate to Translation
2026-09-04
A translational perspective on how Propidium iodide converts membrane integrity and DNA content into actionable evidence in ovarian granulosa-cell research, using AMH–SMAD4 signaling in a PCOS rat model as a mechanistic case study.
-
Anlotinib hydrochloride: Angiogenesis Assay Workflows
2026-09-03
Build a practical endothelial-cell workflow around Anlotinib hydrochloride to measure receptor signaling, migration, and capillary-like network formation. The approach combines concentration-response testing with orthogonal viability and phospho-ERK controls, helping distinguish genuine anti-angiogenic activity from assay artifacts.
-
Etomoxir Workflows for Immunometabolic Research
2026-09-03
Etomoxir enables concentration-aware interrogation of CPT-1-dependent fatty acid oxidation in whole blood, cultured cells, and translational disease models. This guide connects standardized cytokine assays with lipid-metabolism controls, stereochemical documentation, and troubleshooting strategies that help distinguish pathway effects from DGAT-related confounding.
-
Amphotericin B Workflows for Fungal Research
2026-09-02
Build more informative antifungal assays by pairing Amphotericin B exposure with membrane, viability, and immune-signaling readouts. This workflow also adapts protoplast lysis logic from classic membrane research while clearly separating exploratory immune and prion-model applications from direct antifungal testing.
-
Sulfachloropyridazine in E. tenella Cecal Ecology
2026-09-02
The reference study integrated 16S rRNA sequencing and LC-MS/MS metabolomics to examine how Eimeria tenella infection and treatment with ethanamizuril, Sulfachloropyridazine, or their combination reshape the chicken cecal ecosystem. Its main contribution is to connect anticoccidial response with microbiota and metabolite patterns, while showing that low-dose combination treatment did not necessarily produce additive ecological or therapeutic effects.
-
Birinapant (TL32711) for Apoptosis Workflows
2026-09-01
Birinapant (TL32711) converts IAP biology into a practical assay strategy for measuring caspase-8 activation, apoptosis induction in cancer cells, and TRAIL potency enhancement. This guide connects its TNF-sensitive mechanism with MDM1–p53 chemoradiotherapy research while clearly separating established evidence from testable combination hypotheses.